- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
First Helium
Purpose Bitcoin ETF
Soma Gold Corp.
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Eisai and Biogen Idec Collaboration Set to Develop and Commercialize Treatments for Alzheimer’s
Eisai Co., Ltd. (OTCMKTS:ESALY) and Biogen Idec (NASDAQ: BIIB) are collaborating to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. The agreement also provides Eisai the option to jointly develop and commercialize two of Biogen Idec’s candidates for Alzheimer’s, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.
Eisai Co., Ltd. (OTCMKTS:ESALY) and Biogen Idec (NASDAQ: BIIB) are collaborating to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. The agreement also provides Eisai the option to jointly develop and commercialize two of Biogen Idec’s candidates for Alzheimer’s, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.
As quoted in the press release:
The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two candidates: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. These candidates have the potential to reduce Aβ plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression.
Click here to read the Eisai Co. Ltd. (OTCMKTS:ESALY) press release
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.